We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+45.97%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.07B
AUM Growth
+$1.91B
Cap. Flow
+$58.2M
Cap. Flow %
0.82%
Top 10 Hldgs %
40.22%
Holding
232
New
17
Increased
84
Reduced
52
Closed
24

Top Buys

Rank Stock Value
1
GBIO
Generation Bio
GBIO
+$32.1M
2
SYK icon
Stryker
SYK
+$27.9M
3
PODD icon
Insulet
PODD
+$24.7M
4
BMY icon
Bristol-Myers Squibb
BMY
+$24.3M
5
DVA icon
DaVita
DVA
+$23.4M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$78.8M
2
ISRG icon
Intuitive Surgical
ISRG
+$34.5M
3
ILMN icon
Illumina
ILMN
+$34.1M
4
MRNA icon
Moderna
MRNA
+$33.1M
5
AKCA
Akcea Therapeutics Inc
AKCA
+$26.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.05%
2 Industrials 0.58%
3 Technology 0.42%
4 Communication Services 0.29%
5 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
126
AbbVie
ABBV
$458B
$3.63M 0.05%
37,000
+11,600
+46% +$1.02M
BNTX icon
127
BioNTech
BNTX
$22.6B
$3.34M 0.05%
+50,000
New +$2.5M
SRPT icon
128
Sarepta Therapeutics
SRPT
$1.66B
$3.25M 0.05%
20,300
+300
+2% +$40.8K
SNY icon
129
Sanofi
SNY
$104B
$2.91M 0.04%
+57,000
New +$2.77M
PTCT icon
130
PTC Therapeutics
PTCT
$6.37B
$2.88M 0.04%
56,800
-8,400
-13% -$413K
BMY.RT
131
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$2.86M 0.04%
800,000
-16,600
-2% -$59.9K
MNTA
132
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$2.48M 0.04%
74,400
+7,000
+10% +$223K
ACAD icon
133
Acadia Pharmaceuticals
ACAD
$4.25B
$2.18M 0.03%
44,900
+2,900
+7% +$139K
MRTX
134
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.03M 0.03%
17,800
+1,900
+12% +$184K
ASND icon
135
Ascendis Pharma A/S
ASND
$16.7B
$1.97M 0.03%
13,300
+1,400
+12% +$192K
RDY icon
136
Dr. Reddy's Laboratories
RDY
$9.82B
$1.96M 0.03%
+185,000
New +$1.88M
RARE icon
137
Ultragenyx Pharmaceutical
RARE
$2.65B
$1.88M 0.03%
24,000
+2,500
+12% +$165K
VIR icon
138
Vir Biotechnology
VIR
$1.47B
$1.74M 0.02%
+42,500
New +$1.43M
QURE icon
139
uniQure
QURE
$2.68B
$1.55M 0.02%
34,500
+3,000
+10% +$177K
RGNX icon
140
Regenxbio
RGNX
$623M
$1.51M 0.02%
41,000
+4,100
+11% +$153K
CLLS
141
Cellectis
CLLS
$286M
$1.49M 0.02%
83,500
+8,200
+11% +$125K
BNR
142
Burning Rock Biotech
BNR
$1.22M 0.02%
+4,500
New +$1.23M
GTH
143
DELISTED
Genetron Holdings Limited ADS
GTH
$1.21M 0.02%
+33,333
New +$1.35M
YI
144
111 Inc
YI
$1.08M 0.02%
17,053
+5,510
+48% +$393K
NARI
145
DELISTED
Inari Medical, Inc. Common Stock
NARI
$727K 0.01%
+15,000
New +$716K
EA icon
146
Electronic Arts
EA
$52.4B
$617K 0.01%
4,670
-130
-3% -$15.4K
POOL icon
147
Pool Corp
POOL
$6.7B
$598K 0.01%
2,200
– –
MCK icon
148
McKesson
MCK
$98.5B
$597K 0.01%
3,892
– –
MTCH icon
149
Match Group
MTCH
$8.84B
$567K 0.01%
5,300
– –
MTD icon
150
Mettler-Toledo International
MTD
$26.8B
$564K 0.01%
700
– –
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q2 2020 Portfolio in Review

As of Q2 2020, Bellevue Group held 232 positions worth $7.07B, up 37% from $5.16B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group's Q2 2020 filing shows 17 new, 84 increased, 52 reduced and 24 closed positions. Its largest new stake was Generation Bio: 144,000 shares worth $30.2M. The largest sale was Vertex Pharmaceuticals, an estimated $78.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q2 2020 buy was Generation Bio: 144,000 shares worth $30.2M.
  • Bellevue Group added most to Stryker in Q2 2020, an estimated $27.9M increase.
  • Bellevue Group's biggest Q2 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $78.8M.
  • Bellevue Group fully exited QuidelOrtho in Q2 2020, selling an estimated $11.1M.
  • Bellevue Group's ten largest holdings make up 40% of its $7.07B portfolio in Q2 2020.
  • Bellevue Group opened 17 new positions and closed 24 in Q2 2020.
  • Bellevue Group's portfolio value rose 37% quarter-over-quarter to $7.07B.

Based on Bellevue Group's 13F filing for Q2 2020, filed 13 Aug 2020.